Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran PK/PD in Chinese Participants with Elevated LDL-C
NCT04774003Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of inclisiran in hyperlipidemia and hypercholesterolemia (3 arms), sponsored by Novartis. Primary endpoints: Maximum Peak Observed Plasma Inclisiran Concentration, Time to Reach Maximum Peak Plasma Inclisiran Concentration and 4 more. Started Feb 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
hyperlipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT04774003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774003.